La share of penetration of biosimilars in Spain is higher in hospitals (61%) than in pharmacy offices (14%), which gives a average of 28%. Despite this difference, there is a growth of more than 300% in 2020 compared to 2018 in Primary Care, when the penetration was 4%. This has been confirmed this Wednesday Encarnación Cruz, General Director of the Spanish Association of Biosimilar Medicines (Biosim) in the face-to-face (and virtual) meeting Present and future of biosimilars, where he has presented the Biennial Report of Biosim Activities 2019-2020, and has had a few words of remembrance towards her predecessor, Regina Muzquiz, died in 2020. 'She blazed a solid path. I hope to continue contributing to the growth of Biosim, as she asked me to', Cruz recalled.

READ MORE